NBI 921355
Alternative Names: NBI'355; NBI-921355Latest Information Update: 31 Mar 2025
At a glance
- Originator Xenon Pharmaceuticals
- Developer Neurocrine Biosciences
- Class Antiepileptic drugs
- Mechanism of Action NAV1.2 voltage-gated sodium channel inhibitors; Nav1.6 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Epilepsy